Showing 2231-2240 of 3568 results for "".
- Feet Get Skin Cancer Too, ACFAS Warnshttps://practicaldermatology.com/news/feet-get-skin-cancer-too-acfas-warns/2458565/Skin cancer of the foot is prevalent and can be fatal if not caught early, the American College of Foot and Ankle Surgeons (ACFAS) warns. While all types of skin cancer, including squamous cell and basal cell carcinoma, can be found
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Tight Ponytails, Braids Linked to Traction Alopeciahttps://practicaldermatology.com/news/tight-ponytails-braids-linked-to-traction-alopecia/2458588/New research confirms a “strong association” between scalp-pulling hairstyles such as tight ponytails, braids, knots and buns and the development of traction alopecia. The review study is published ahead of print in the
- Study: Viveve® Improves Vaginal Laxityhttps://practicaldermatology.com/news/study-viveve-improves-vaginal-laxity/2458595/The Viveve System improves vaginal laxity when compared with a sham procedure, a new study suggests. Top-line results from the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE 1) show that the procedure is both safe and effec
- Study on TRASER for Nasal Spider Veins Scores Top Honors from ASLMShttps://practicaldermatology.com/news/study-on-traser-for-nasal-spider-veins-scores-top-honors-from-aslms/2458606/Houston dermatologist Paul M. Friedman, MD won the Best of Cutaneous Applications Abstract Session Award for his paper on the use of a novel optical device to treat vexing nasal telangiectasias. The award was presented at the 2016 Annual Conference of the American S
- Vitae Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor for Psoriasishttps://practicaldermatology.com/news/vitae-achieves-proof-of-concept-with-first-in-class-roryt-inhibitor-for-psoriasis/2458643/Vitae Pharmaceuticals, Inc. shared positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple a
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Galderma Laboratories Launches qilib Hair Care Linehttps://practicaldermatology.com/news/galderma-laboratories-launches-qilib-hair-care-line/2458659/Galderma Laboratories, L.P., launched qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement. The qilib portfolio features a dual action system to address hair thinning and hair loss. Despite the 80 million men and women in the US who suff
- Cipher Launches Bionect Foamhttps://practicaldermatology.com/news/cipher-launches-bionect-foam/2458678/Cipher Pharmaceuticals’ prescription topical Bionect® is now available in the US in a lightweight foam preparation that holds its shape until application. The company says the for
- CMS: 2015 Hardship Exemption Does Not Impede EHR Incentiveshttps://practicaldermatology.com/news/cms-2015-hardship-exemption-does-not-impede-her-incentives/2458686/The